Inside you'll find a comprehensive overview of our actions, results and outlook for the year ahead.
Click here to read it
2024 was marked in particular by the development of a pioneering approach in the prenatal field and the launch of a new program targeting pre-eclampsia and fetal growth retardation.
We have also initiated important work on an ethical and regulatory framework for the development of prenatal therapies.
The World Health Organization also adopted its first-ever resolution on rare diseases, an event that underlines the urgency and relevance of our mission.
